These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38028276)

  • 1. Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab.
    Suehiro E; Ishihara H; Kogeichi Y; Ozawa T; Haraguchi K; Honda M; Honda Y; Inaba M; Kabeya R; Kanda N; Koketsu K; Murakami N; Nakamoto H; Oshio K; Saigusa K; Shuto T; Sugiyama S; Suzuyama K; Terashima T; Tsuura M; Nakada M; Kobata H; Higashi T; Sakai N; Suzuki M
    Neurotrauma Rep; 2023; 4(1):790-796. PubMed ID: 38028276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarucizumab for a traumatic head injury patient taking dabigatran.
    Maruyama S; Hayakawa K; Kanayama S; Iwamura H; Wada D; Saito F; Nakamori Y; Kuwagata Y
    Int J Emerg Med; 2018 Oct; 11(1):41. PubMed ID: 31179930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe Burr Hole Surgery for Chronic Subdural Hematoma Using Dabigatran with Idarucizumab.
    Arai N; Mine Y; Kagami H; Maruyama M; Daikoh A; Inaba M
    World Neurosurg; 2018 Jan; 109():432-435. PubMed ID: 29054780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.
    Lu VM; Phan K; Rao PJ; Sharma SV; Kasper EM
    Clin Neurol Neurosurg; 2019 Jun; 181():76-81. PubMed ID: 31015061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
    Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Abraham A; Althaus K; Becks G; Berrouschot J; Berthel J; Bode FJ; Burghaus L; Cangür H; Daffertshofer M; Edelbusch S; Eggers J; Gerlach R; Gröschel K; Große-Dresselhaus F; Günther A; Haase CG; Haensch CA; Harloff A; Heckmann JG; Held V; Hieber M; Kauert A; Kern R; Kerz T; Köhrmann M; Kraft P; Kühnlein P; Latta J; Leinisch E; Lenz A; Leithner C; Neumann-Haefelin T; Mäurer M; Müllges W; Nolte CH; Obermann M; Partowi S; Patzschke P; Poli S; Pulkowski U; Purrucker J; Rehfeldt T; Ringleb PA; Röther J; Rossi R; El-Sabassy H; Sauer O; Schackert G; Schäfer N; Schellinger PD; Schneider A; Schuppner R; Schwab S; Schwarte O; Seitz RJ; Senger S; Shah YP; Sindern E; Sparenberg P; Steiner T; Szabo K; Urbanek C; Sarnowksi BV; Weissenborn K; Wienecke P; Witt K; Wruck R; Wunderlich S
    Int J Stroke; 2020 Aug; 15(6):609-618. PubMed ID: 31955706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience with idarucizumab as a reverse agent of dabigatran].
    Bottaro FJ; Margan MM; Duboscq C; Ceresetto JM
    Medicina (B Aires); 2020; 80(4):405-410. PubMed ID: 32841148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients.
    Frol S; Sernec LP; Hudnik LK; Šabovič M; Oblak JP
    CNS Drugs; 2021 Feb; 35(2):233-242. PubMed ID: 33548038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy.
    Kikule I; Baborikina A; Haritoncenko I; Karelis G
    Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295516
    [No Abstract]   [Full Text] [Related]  

  • 11. Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.
    Izaguirre Ávila R; Bahena López JE; Cortina de la Rosa E; Hernández Márquez MÁ
    Eur Heart J Case Rep; 2019 Jun; 3(2):. PubMed ID: 31449648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness and safety of idarucizumab in the management of perioperative complications of atrial fibrillation catheter ablation in atrial fibrillation patients under dabigatran therapy].
    Li SN; Zhang JR; Li CY; Dai WL; Jia CQ; Li X; Ning M; Du X; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Mar; 49(3):217-223. PubMed ID: 33706454
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.
    Edwards G; Roman C; Jithoo R; Mitra B
    Trauma Case Rep; 2018 Feb; 13():46-49. PubMed ID: 29644298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
    Ohtani T; Sintoku R; Yajima T; Kaneko N
    J Med Case Rep; 2019 Dec; 13(1):390. PubMed ID: 31875786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series.
    Peacock WF; Grotta JC; Steiner T
    J Emerg Med; 2019 Dec; 57(6):e167-e173. PubMed ID: 31662218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
    Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Althaus K; Berrouschot J; Cangür H; Daffertshofer M; Edelbusch S; Gröschel K; Haase CG; Harloff A; Held V; Kauert A; Kraft P; Lenz A; Müllges W; Obermann M; Partowi S; Purrucker J; Ringleb PA; Röther J; Rossi R; Schäfer N; Schneider A; Schuppner R; Seitz RJ; Szabo K; Wruck R
    Int J Stroke; 2017 Jun; 12(4):383-391. PubMed ID: 28494694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful dabigatran reversal after subdural hemorrhage using idarucizumab in a mobile stroke unit: A case report.
    Thirunavukkarasu S; Kalashyan H; Jickling G; Jeerakathil TJ; Jayaprakash HK; Buck BH; Shuaib A; Butcher K
    Medicine (Baltimore); 2020 May; 99(21):e20200. PubMed ID: 32481289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
    Shin SS; Marsh EB; Ali H; Nyquist PA; Hanley DF; Ziai WC
    Neurocrit Care; 2020 Apr; 32(2):407-418. PubMed ID: 32034657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.